Nature Communications has published a retraction note concerning a study titled “Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms.”
The research examined diffuse gliomas through proteogenomics, an approach used to investigate molecular characteristics at the protein and genetic levels. Its reported focus included identifying disease subtypes, potential treatment targets and mechanisms linked to immune evasion.
The notice is associated with research conducted through biomedical and genetics institutions, including the State Key Laboratory of Genetic Engineering and related centers listed in the publication information. The available notice does not provide further details here about the circumstances behind the retraction.
The retraction changes the publication status of the study and distinguishes the notice from the original findings about diffuse glioma biology, treatment strategies and tumor interactions with the immune system.
